ARAna Socorro Rodríguez-Báez

Ana Socorro Rodríguez-Báez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ana Socorro Rodríguez-Báez has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Application of Pharmacometric Modelling Towards Precise Dosing in Neonates, Infants and Toddlers: A Scoping Review

    by Ana S. Rodríguez-Báez, Nina Kreuzberger, Claire Iannizzi, Kamran Irfan, Frederike Lentz, Anna Krueger, Norbert Benda, Ulrich Jaehde

  • Open Access

    Population pharmacokinetics and dose optimization of piperacillin-tazobactam in premature and term neonates with severe infections

    by Frida S. Boer-Pérez, Victoria Lima-Rogel, Silvia Romano-Moreno, Ana R. Mejía-Elizondo, Susanna E. Medellín-Garibay, Paula Schaiquevich, Daniel E. Noyola-Cherpitel, Ana S. Rodríguez-Báez, Cristian J. Rodríguez-Pinal, Rosa del C. Milán-Segovia

    Piperacillin-tazobactam is widely used off-label in neonates for the empirical treatment of severe infections, resulting in diverse dosing regimens across clinical settings. This variability, combined with high interindividual differences in renal maturation that impact drug disposition, complicates standardized dosing and emphasizes the need for individualized, evidence-based strategies. This study aimed to develop and evaluate a population pharmacokinetic model of piperacillin in neonates to support optimized initial dosing recommendations. Neonatal patients (postnatal age ≤28 days) admitted to an intensive care unit who received piperacillin-tazobactam (8:1 ratio) at Neofax-recommended doses were included. Plasma concentrations were measured using an ultra-high-performance liquid chromatography with tandem mass spectrometry method. Population pharmacokinetic analysis for piperacillin was performed using nonlinear mixed-effects modeling. A total of 65 blood samples were collected from 25 neonates, both preterm (56%) and full-term. Piperacillin pharmacokinetics was best described by a one-compartment model incorporating body weight-based allometric scaling, postmenstrual age, and serum creatinine as covariates influencing clearance. For a typical neonate in the study (1.76 kg), the estimated clearance was 0.748 L/h (coefficient of variation, 38.3%), and the volume of distribution was 0.866 L (37.7%). Simulations indicated adequate probability of target attainment with current recommendations, but a high proportion of preterm neonates (>75%) were at risk of overexposure (trough piperacillin plasma concentration >50 mg/L). Additional simulations supported individualized initial regimens based on renal maturation and suggested that extended infusions (1−4 h) may improve target attainment for stricter targets and less-susceptible pathogens. This study provides a validated pharmacokinetic model for piperacillin in neonates with severe infections, offering a framework to optimize empiric dosing based on renal function and developmental stage.


  • External Evaluation of Population Pharmacokinetic Models of Piperacillin in Preterm and Term Patients from Neonatal Intensive Care

    by Frida S. Boer-Pérez, Victoria Lima-Rogel, Ana R. Mejía-Elizondo, Susanna E. Medellín-Garibay, Ana S. Rodríguez-Báez, Cristian J. Rodríguez-Pinal, Rosa del C. Milán-Segovia, Silvia Romano-Moreno

    Background and Objectives Piperacillin/tazobactam is extensively used off-label to treat late-onset neonatal sepsis, but safety and pharmacokinetic data in this population are limited. Additionally, the organic immaturity of the newborns contributes to a high piperacillin pharmacokinetic variability. This affects the clinical efficacy of the antibiotic treatment and increases the probability of developing drug resistance. This study aimed to evaluate the predictive performance of reported piperacillin population pharmacokinetic models for their application in a model-informed precision dosing strategy in preterm and term Mexican neonatal intensive care patients. Methods Published population pharmacokinetic models for piperacillin which included neonates in their study population were identified. From the reference models, structured models, population pharmacokinetic parameters, and interindividual and residual variability data were extracted to be replicated in pharmacokinetic software (NONMEM® version 7.4). For the clinical study, a sampling schedule was designed, and 2–3 blood samples of 250 µL were taken from neonates who met the inclusion criteria. Piperacillin plasma concentrations were determined by liquid chromatography/tandem mass spectrometry. The clinical treatment data were collected, and piperacillin plasma concentrations were estimated using reference pharmacokinetic models for an a priori or Bayesian approach. Statistical methods were used in terms of bias and precision to evaluate the differences between observed and estimated neonatal piperacillin plasma concentrations with the different approaches and to identify the pharmacokinetic model that best fits the neonatal data. Results A total of 70 plasma samples were collected from 25 neonatal patients, of which 15 were preterm neonates. The overall median value (range) postnatal age, gestational age, body weight, and serum creatinine at the sampling collecting day were 12 (3–26) days, 34.2 (26–41.1) weeks, 1.78 (0.08–3.90) Kg, 0.47 (0.20–0.90) mg/dL, respectively. Three population pharmacokinetic models for piperacillin in infants up to 2 months were identified, and their predictive performance in neonatal data was evaluated. No pharmacokinetic model was suitable for our population using an a priori approach. The model published by Cohen-Wolkowiez et al. in 2014 with a Bayesian approach showed the best performance of the pharmacokinetic models evaluated in our neonatal data. The procedure requires two blood samples (predose and postdose), and, when applied, it predicted 66.6% of the observations with a relative median absolute predicted error of less than 30%. Conclusions The population pharmacokinetic model developed by Cohen-Wolkowiez et al. in 2014 demonstrated superior performance in predicting the plasma concentration of piperacillin in preterm and term Mexican neonatal intensive care patients. The Bayesian approach, including two different piperacillin plasma concentrations, was clinically acceptable regarding bias and precision. Its application for model-informed precision dosing can be an option to optimize the piperacillin dosage in our population.


  • A population approach of rifampicin pharmacogenetics and pharmacokinetics in Mexican patients with tuberculosis

    by Susanna Edith Medellin-Garibay, Ana Patricia Huerta-García, Ana Socorro Rodríguez-Báez, Martín Magaña-Aquino, Arturo Ortiz-Álvarez, Diana Patricia Portales-Pérez, Rosa del Carmen Milán-Segovia, Silvia Romano-Moreno